Every Form 4 that CAMP4 Therapeutics Corporation (CAMP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CAMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAMP filings page.
Camp4 Therapeutics Corp (CAMP) reported that Chief Financial Officer Kelly Gold filed a Form 4 showing an open-market purchase associated with her household of 10,000 shares of Common Stock on August 31, 2026, at a weighted average price of $3.96 per share, in multiple trades between $3.88 and $4.00. These shares are held in a brokerage account in the name of her spouse, over which she does not exercise investment control and for which she disclaims beneficial ownership except for any pecuniary interest. Separately, Gold is reported to hold 76,467 shares directly, including 2,039 shares previously acquired under Camp4 Therapeutics Corporation’s Employee Stock Purchase Plan.
Camp4 Therapeutics Corp (CAMP) director Andrew J. Schwab, through an affiliated investment fund, reported selling 400,000 shares of common stock on 2026-08-27 at $4.04 per share. After this sale, 5AM Ventures VI, L.P. held 2,033,270 shares, and affiliated funds 5AM Ventures VII, L.P. and 5AM Opportunities II, L.P. held 2,941,176 and 302,770 shares, respectively. The filing states these positions are held indirectly through 5AM entities and that Schwab disclaims beneficial ownership beyond his pecuniary interest.
Camp4 Therapeutics Corp (CAMP) director Andrew J. Schwab reported a small sale of 10 shares of common stock on 2026-08-24 at $4.50 per share. The shares are held indirectly through 5AM Ventures VI, L.P., with Schwab reporting shared voting and investment power through his role at its general partner and disclaiming beneficial ownership except for his pecuniary interest.
Following this transaction, entities associated with Schwab reported indirect holdings of 2,433,270 shares via 5AM Ventures VI, L.P., 2,941,176 shares via 5AM Ventures VII, L.P., and 302,770 shares via 5AM Opportunities II, L.P. The filing does not indicate use of a Rule 10b5-1 trading plan.
Camp4 Therapeutics Corp (CAMP) reports that director Andrew J. Schwab, through affiliated fund 5AM Ventures VI, L.P., sold 191,865 shares of Common Stock over August 19–21, 2026 in open-market or private transactions. The sales were indirect, by 5AM Ventures VI, with Schwab disclaiming beneficial ownership beyond his pecuniary interest.
The sales comprised 45,147 shares on August 19 at a weighted average $4.76 (individual trades from $4.75–$5.00), 114,700 shares on August 20 at a weighted average $4.54 (from $4.50–$4.91), and 32,018 shares on August 21 at a weighted average $4.50 (from $4.50–$4.53). Separate holding entries show 2,941,176 shares held by 5AM Ventures VII, L.P. and 302,770 shares held by 5AM Opportunities II, L.P., both reported as indirect interests with similar beneficial-ownership disclaimers.
Camp4 Therapeutics Corp (CAMP) reported an insider sale by Chief Scientific Officer Daniel Tardiff. On August 19, 2026, he sold 1,738 shares of common stock in a sale characterized as an open market or private transaction at $4.76 per share. Following this transaction, his reported direct holdings of common stock from this lot were 0 shares. The shares had been previously acquired through the company’s Employee Stock Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026 in a transaction described as exempt under Rule 16b-3(c).
Camp4 Therapeutics Corp reported that major shareholder 5AM Ventures VII, L.P. purchased 3,179,558 pre-funded warrants at $1.5299 per warrant. Each warrant is exercisable immediately for one share of common stock at $0.0001 per share, has no expiration, and is subject to a 9.99% beneficial ownership cap. The warrants are held indirectly through 5AM Ventures VII, with related entities and individuals disclaiming beneficial ownership beyond their pecuniary interests.
Camp4 Therapeutics Corp director Andrew J. Schwab reported that affiliated fund 5AM Ventures VII, L.P. received 3,179,558 Pre-Funded Warrants to buy an equal number of common shares at an exercise price of 0.0001 per share. The warrants are immediately exercisable, have no expiration, and include a 9.99% beneficial ownership cap for Ventures VII and its Attribution Parties.
Camp4 Therapeutics Corp director Richard A. Young purchased 16,378 shares of common stock on August 3, 2026 at $1.65 per share. The shares were acquired in the second closing of a private placement under a Securities Purchase Agreement, increasing his direct holdings to 186,388 shares.
Camp4 Therapeutics Corp Chief Medical Officer Yuri Maricich purchased 6,551 shares of common stock on August 3, 2026 in the second closing of a private placement at $1.65 per share under a Securities Purchase Agreement. After this transaction, he directly holds 12,611 common shares.
Camp4 Therapeutics Corp disclosed that its Chief Financial Officer, Kelly Gold, purchased 6,551 shares of common stock on August 3, 2026 at $1.65 per share. The shares were acquired in the second closing of a private placement under a Securities Purchase Agreement with the issuer and various investors. Following this transaction, Gold directly owns 74,428 shares of Camp4 Therapeutics common stock. The Rule 10b5-1 checkbox was not marked for this transaction.
Camp4 Therapeutics Corp director and Chief Executive Officer Josh Mandel-Brehm purchased 6,551 shares of common stock on August 3, 2026, at $1.65 per share. The shares were acquired in the second closing of a private placement under a Securities Purchase Agreement dated September 9, 2025, as amended August 3, 2026. Following this purchase, he directly owned 284,968 shares of Camp4 common stock.
Camp4 Therapeutics Corp director Douglas E. Williams received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036. All 28,000 underlying shares vest together on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, assuming continued service through that date.
Camp4 Therapeutics Corp director Richard A. Young reported receiving a compensation grant of stock options. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.34 per share, expiring on June 9, 2036.
The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, as long as he continues serving the company through that date. After this grant, he holds options for 28,000 shares directly.
Camp4 Therapeutics director and 10% owner Andrew J. Schwab reported receiving a grant of stock options representing 28,000 shares of common stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036. According to the footnote, all shares underlying the option vest on the earlier of the first anniversary of the grant date or the issuer's next annual stockholder meeting, contingent on continued service. After this grant, Schwab holds 28,000 options directly.
Camp4 Therapeutics director Steven H. Holtzman received a grant of stock options for 28,000 shares of common stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036. All 28,000 options vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, as long as he continues serving the company through that date.
Camp4 Therapeutics Corp director Stewart Murray received a grant of stock options covering 28,000 shares of Common Stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036.
The 28,000 underlying shares vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, provided Murray continues service with Camp4 Therapeutics through that vesting date. Following this grant, his directly held option position reported in this filing is 28,000 options.
Camp4 Therapeutics Corp director and 10% owner Amir Nashat received a grant of stock options for 28,000 shares of common stock. The options have an exercise price of $4.34 per share and no cash was paid at grant. They vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, as long as Nashat continues to provide service through that date. After this grant, he holds options for 28,000 shares, which expire on June 9, 2036.
Camp4 Therapeutics Corp Chief Scientific Officer Daniel Tardiff received a grant of stock options covering 170,000 shares of common stock. The options have an exercise price of $4.46 per share and expire on March 31, 2036.
The options vest in equal monthly installments over four years starting from the grant date, aligning compensation with long-term company performance. Following this award, Tardiff holds 170,000 stock options directly, reflecting a routine, compensation-related equity grant rather than an open-market trade.
Camp4 Therapeutics reported that Chief Medical Officer Yuri Maricich received a grant of stock options covering 215,000 shares of common stock. The options have an exercise price of $4.46 per share, expire on March 31, 2036, and vest in equal monthly installments over four years from the grant date.
Camp4 Therapeutics Corp Chief Financial Officer Kelly Gold received a grant of stock options covering 215,000 shares of common stock. The options have an exercise price of $4.46 per share and expire in 2036.
The shares underlying the option vest in equal monthly installments over four years from the grant date, meaning the award functions as long-term, time-based compensation rather than an immediate cash transaction.
Camp4 Therapeutics Corp reported that Chief Executive Officer Josh Mandel-Brehm received a grant of stock options on Common Stock. The award covers 580,000 shares with an exercise price of $4.46 per share and an expiration date of March 31, 2036.
The options vest in equal monthly installments over four years starting from the grant date, meaning the award is earned gradually over time. Following this grant, Mandel-Brehm holds stock options covering 580,000 shares directly.
Camp4 Therapeutics director Michael F. MacLean received a new stock option award for 56,000 shares of common stock. The option has an exercise price of $4.46 per share and expires on March 31, 2036. This is a compensation-related grant, not an open-market purchase.
The option covers 56,000 underlying shares and was awarded at no cost on the grant date. The shares underlying the option vest in equal monthly installments over three years starting from the grant date, so MacLean earns the right to exercise portions of the award gradually over time.